These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7520313)

  • 1. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis.
    Butler SL; Nelson JW; Poxton IR; Govan JR
    FEMS Immunol Med Microbiol; 1994 May; 8(4):285-92. PubMed ID: 7520313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IgG response to Burkholderia cepacia outer membrane antigens in cystic fibrosis: assessment of cross-reactivity with Pseudomonas aeruginosa.
    Lacy DE; Smith AW; Stableforth DE; Smith G; Weller PH; Brown MR
    FEMS Immunol Med Microbiol; 1995 Feb; 10(3-4):253-61. PubMed ID: 7539670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to Burkholderia cepacia in patients with cystic fibrosis colonized with Burkholderia cepacia and Pseudomonas aeruginosa.
    Hendry J; Butler S; Elborn JS; Govan JR; Nelson J; Shale DJ; Webb AK
    J Infect; 2000 Mar; 40(2):164-70. PubMed ID: 10841094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis.
    Simpson IN; Finlay J; Winstanley DJ; Dewhurst N; Nelson JW; Butler SL; Govan JR
    J Antimicrob Chemother; 1994 Sep; 34(3):353-61. PubMed ID: 7530242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis.
    Nelson JW; Butler SL; Brown PH; Greening AP; Govan JR
    J Med Microbiol; 1993 Jul; 39(1):39-47. PubMed ID: 7686977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloaking antibodies are prevalent in
    Pham A; Tan KKY; Ledger EL; Smith DJ; Reid DW; Burr L; Chambers DC; Wells TJ
    Front Cell Infect Microbiol; 2024; 14():1426773. PubMed ID: 39193503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum IgG response to an outer membrane porin protein of Burkholderia cepacia in patients with cystic fibrosis.
    Lacy DE; Smith AW; Lambert PA; Peckham D; Stableforth DE; Smith EG; Desai M; Weller PH; Brown MR
    FEMS Immunol Med Microbiol; 1997 Feb; 17(2):87-94. PubMed ID: 9061354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis.
    Aronoff SC; Quinn FJ; Stern RC
    Pediatr Pulmonol; 1991; 11(4):289-93. PubMed ID: 1722035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining potential targets for immunotherapy in Burkholderia cepacia infection.
    Burnie JP; al-Wardi EJ; Williamson P; Matthews RC; Webb K; David T
    FEMS Immunol Med Microbiol; 1995 Jan; 10(2):157-64. PubMed ID: 7536517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary function, serum markers of inflammation, and IgG antibodies to core lipopolysaccharide of Burkholderia cepacia in adults with cystic fibrosis, following colonization with Burkholderia cepacia.
    Hendry J; Nixon L; Dodd M; Elborn JS; Govan J; Shale DJ; Webb AK
    Pediatr Pulmonol; 2000 Jan; 29(1):8-10. PubMed ID: 10613780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.
    Hughes JE; Stewart J; Barclay GR; Govan JR
    Infect Immun; 1997 Oct; 65(10):4281-7. PubMed ID: 9317038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients.
    Sajjan U; Corey M; Humar A; Tullis E; Cutz E; Ackerley C; Forstner J
    J Med Microbiol; 2001 Jun; 50(6):535-546. PubMed ID: 11393291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide chemotypes of Burkholderia cepacia.
    Evans E; Poxton IR; Govan JRW
    J Med Microbiol; 1999 Sep; 48(9):825-832. PubMed ID: 10482293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.
    Vandamme P; Holmes B; Vancanneyt M; Coenye T; Hoste B; Coopman R; Revets H; Lauwers S; Gillis M; Kersters K; Govan JR
    Int J Syst Bacteriol; 1997 Oct; 47(4):1188-200. PubMed ID: 9336927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.
    Hancock RE; Mutharia LM; Chan L; Darveau RP; Speert DP; Pier GB
    Infect Immun; 1983 Oct; 42(1):170-7. PubMed ID: 6413410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subspecific differentiation of Burkholderia cepacia isolates in cystic fibrosis.
    Livesley MA; Baxter IA; Lambert PA; Govan JR; Weller PH; Lacey DE; Allison DG; Giwercman B; Hoiby N
    J Med Microbiol; 1998 Nov; 47(11):999-1006. PubMed ID: 9822299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burkholderia cepacia: medical, taxonomic and ecological issues.
    Govan JR; Hughes JE; Vandamme P
    J Med Microbiol; 1996 Dec; 45(6):395-407. PubMed ID: 8958242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide-induced potentiation of the killing of Burkholderia cepacia by reactive oxygen species: implications for cystic fibrosis.
    Smith AW; Green J; Eden CE; Watson ML
    J Med Microbiol; 1999 May; 48(5):419-423. PubMed ID: 10229538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.